Publicaciones científicas

Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
Alvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A.
Clinical Cancer Research , 19: 2677-2687. FI: 7,742 (Q1) (D1)
PubMed
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications
Garcia-Gomez A; Ocio EM; Pandiella A; San Miguel JF; Garayoa M.
Investigational New Drugs , 31: 200-205. FI: 3,357 (Q1) (D3)
PubMed
Targeting HER receptors in cancer
Ocaña A; Pandiella A.
Current Pharmaceutical Design , 19: 808-817. FI: 3,870 (Q1) (D2)
PubMed
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia , 27: 430-440. FI: 9,561 (Q1) (D1)
PubMed
The evolving landscape of protein kinases in breast cancer: Clinical implications
Ocaña A; Amir E; Seruga B; Martin M; Pandiella A.
Cancer Treatment Reviews , 39: 68-76. FI: 6,054 (Q1) (D2)
PubMed

45 resultados

Páginas: < 1 2 3 4 5